Exploiting Pseudomonas putida for drug development

Chem Biol. 2005 Mar;12(3):261. doi: 10.1016/j.chembiol.2005.02.008.

Abstract

In this issue of Chemistry & Biology, a strategy that combines large DNA fragment recombineering in Escherichia coli and heterologous expression in Pseudomonas putida is described. The work focuses on myxochromide S, a natural compound produced by Stigmatella aurantiaca.

Publication types

  • Review

MeSH terms

  • DNA, Recombinant / biosynthesis
  • DNA, Recombinant / genetics
  • Drug Design*
  • Genes, Synthetic*
  • Genetic Engineering / methods*
  • Genetic Engineering / trends*
  • Proteobacteria / chemistry
  • Proteobacteria / genetics
  • Pseudomonas putida / chemistry*
  • Pseudomonas putida / genetics
  • Pseudomonas putida / metabolism

Substances

  • DNA, Recombinant